



Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-_{XL}

Jung Jin Hwang^{1,2} · Yong Sook Kim² · Taelim Kim² · Mi Joung Kim² · In Gab Jeong³ · Je-Hwan Lee⁴ · Jene Choi⁵ · Sejin Jang⁵ · Seonggu Ro⁶ · Choung-Soo Kim³

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Correction to: Invest New Drugs (2012) 30:1434–1442
<https://doi.org/10.1007/s10637-011-9718-1>

The blots of control and docetaxel for caspase-9, caspase-3, caspase-8, Bcl-_{XL}, and tubulin in the Figure 4f were reused from Figure 4 of our previous paper published in *Journal of Urology* in 2010 (<https://doi.org/10.1016/j.juro.2010.07.035>).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s10637-011-9718-1>

✉ Choung-Soo Kim
cskim@amc.seoul.kr

¹ Department of Convergence Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

² Institute for Innovative Cancer Research, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

³ Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-Gu, Seoul 05505, South Korea

⁴ Department of Internal Medicine & Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

⁵ Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, South Korea

⁶ PiMedBio, Inc., Seoul 06367, South Korea